Oncternal Therapeutics ONCT
$ 0.53
-24.12%
Quarterly report 2024-Q3
added 11-06-2024
Country |
USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
CEO |
Dr. James Breitmeyer |
Employees in the company |
11 |
Shares |
2.94 M |
Market Cap[1] |
$ 1.56 M |
EBITDA (LTM) |
$ -42.7 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.